In the quest towards building high-performing teams, biopharma can lift a page from the tech playbook around agile organizations. This blog builds upon comparisons with tech relating to business model, investment returns and the dynamics of the different VC ecosystems. In this post, I would like to draw lessons from how tech startups actually work and organize themselves.
This blog was written by Jonathan Montagu, CEO and co-founder of Hotspot Therapeutics, as part of the From The Trenches feature of LifeSciVC.
A year after Ron Renaud’s team at RaNA bagged rights to an RNA platform at Shire and relaunched as Translate Bio, the group has scored a big pharma alliance with Sanofi.
Today, Zafgen announced my resignation from their Board of Directors after 12 years of service.
It’s a bittersweet moment for me: having been there since the beginning, I’ve watched, and supported, the Zafgen story through all the ups and downs that a dozen years can bring. My partners and I at Atlas Venture remain significant investors and supporters of Zafgen and its mission; my departure has nothing to do with a lack of enthusiasm, and my partner Peter Barrett remains Zafgen’s chairman.
Atlas Venture, a leading early stage biotech venture capital firm, today announced that Andrea Armstrong has joined as chief talent officer. Andrea will lead the talent acquisition efforts for Atlas and work closely with companies incubating at Atlas and across the emerging portfolio on recruiting and organizational development.